Development of anti-CSP monoclonal antibody to prevent malalia
Preclinical development of anti- CSP monoclonal antibody to prevent malaria
SEE ALL PARTNER ORGANIZATIONS
Objectives
- Preclinical development of a monoclonal antibody to prevent P. falciparum malaria
In October 2021, the WHO recommended the world’s first RTS, S malaria vaccine (RTS, S) to immunize children in endemic areas. RTS.S shows the efficacy by inducing high-titer antibodies against the amino acid repeat region of the CS protein (CSP) of Plasmodium falciparum. This project aims to isolate and develop a potent anti-CSP monoclonal antibody (mAb) for malaria, and conduct preclinical and clinical development as a preventive antibody drug for malaria.
Results and milestones
A unique innovative advantage of this project is the access of CS-specific antibodies from volunteers who were protected following immunization with the RTS,S vaccine. Consistent with the immunodominance of the protective CS-specific epitopes in the RTS,S vaccine, our panel of well-characterized plasmablasts contains a high proportion of sequences specific for our target epitope (i.e. CS-repeats). This focused approach differs from other projects where CS antibodies were from volunteers either immunized with irradiated sporozoites or naturally infected.
We start with “end” in mind and bring in a “line of sight” approach to conduct CoGs analysis and development of iPDPP for mAbs as tools for malaria intervention. This is to ensure rigorous assessment of the critical value drivers to attain cost effectiveness and high community acceptance, as well as inform our TPP.
Geographic Reach
- Global Commitment
Disease Area
- Infectious and Parasitic Disease
Target Population
- Men
- Women
- People with low incomes
Partner organizations
Ehime University
PATH
Geographic Reach
Global Commitment
Disease Area
Infectious and Parasitic Disease
- Malaria